TP53 and neoplasm: There could be two mechanisms of neoantigen loss in a resistant tumor: 1) through the immune elimination of neoantigen‐containing tumor cells that represent a subset of the tumor population, and 2) through the occurrence of one or more genetic events in a tumor cell that results in neoantigen loss, followed by selection and expansion of the resistant clone.37 Frameshift mutation in neoantigens provide a unique opportunity to target common tumor‐suppressor genes such as TP53 and BAP1, and frameshift indels trigger an increased quantity of neoantigens and greater mutant binding specificity.39